JJ
ALDX icon

Johnson & Johnson’s Aldeyra Therapeutics ALDX Stock Holding History

Johnson & Johnson’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-299,669
Closed -$992K – 21
2024
Q2 		$992K Hold
299,669
– – 0.25% 16
2024
Q1 		$980K Hold
299,669
– – 0.02% 16
2023
Q4 		$1.05M Sell
299,669
-95,165
-24% -$294K 0.02% 17
2023
Q3 		$2.64M Hold
394,834
– – 0.97% 13
2023
Q2 		$3.31M Hold
394,834
– – 1.03% 13
2023
Q1 		$3.92M Hold
394,834
– – 1.28% 14
2022
Q4 		$2.75M Hold
394,834
– – 0.8% 14
2022
Q3 		$2.11M Hold
394,834
– – 0.62% 15
2022
Q2 		$1.57M Hold
394,834
– – 0.4% 15
2022
Q1 		$1.75M Hold
394,834
– – 0.33% 18
2021
Q4 		$1.58M Hold
394,834
– – 0.18% 18
2021
Q3 		$3.47M Buy
+394,834
New +$3.62M 0.3% 17

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Johnson & Johnson's ALDX Position: Q3 2024 in Review

Johnson & Johnson sold out of Aldeyra Therapeutics (ALDX) in Q3 2024, closing a stake of 299,669 shares — an estimated $992K sold.

Johnson & Johnson first reported a position in ALDX in Q3 2021 and held it in 12 quarters. The position peaked at $3.92M in Q1 2023. 112 funds tracked by Wall St. Rank hold ALDX as of Q3 2024.

  • Johnson & Johnson reported no remaining Aldeyra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Johnson & Johnson sold 299,669 Aldeyra Therapeutics shares in Q3 2024, an estimated $992K.
  • Johnson & Johnson first reported a position in Aldeyra Therapeutics in Q3 2021 and held it in 12 quarters.
  • Johnson & Johnson's Aldeyra Therapeutics position peaked at $3.92M in Q1 2023.
  • 112 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2024.

Based on Johnson & Johnson's 13F filing for Q3 2024, filed 13 Nov 2024.